Seeking AlphaTue, 05 May 2026 21:31:15 GMTViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease TranscriptVRDN+3.33%
BenzingaTue, 05 May 2026 14:21:48 GMTViridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease MarketVRDN+3.33%
Investors Business DailyTue, 05 May 2026 12:00:47 GMTHow This Amgen Rival, Up 30%, Plans To Shake Its Grip In Thyroid Eye DiseaseVRDN+3.33%
Seeking AlphaThu, 02 Apr 2026 17:12:11 GMTViridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease TranscriptVRDN+3.33%
Zacks Investment ResearchWed, 01 Apr 2026 13:10:26 GMTViridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?VRDN+3.33%
Investors Business DailyMon, 30 Mar 2026 13:19:56 GMTViridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease ResultsVRDN+3.33%
The Motley FoolSat, 21 Mar 2026 22:13:31 GMTThis Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should KnowVRDN+3.33%
Zacks Investment ResearchThu, 26 Feb 2026 16:01:58 GMTViridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue EstimatesVRDN+3.33%
The Motley FoolMon, 23 Feb 2026 15:26:08 GMTViridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million StakeVRDN+3.33%
